Masked T‑cell Engagers: Cancer Immunotherapies for the Future?

Masked T‑cell engagers: Cancer immunotherapies for the future?

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own immune arsenal to fight cancer.

Masked T-cell engagers: cancer immunotherapies for the future?

T-cells, a type of immune cell, can be used to attack cancer cells. Lightspring/ ShutterstockA new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer. In the trial, which is still in progress and has not yet undergone peer-review, patients with advanced prostate cancer who h…